רווח לפני תשלום ריבית, מסים ופחת: intelliatx.com (NTLA)

Intellia Therapeutics (NTLA) develops innovative treatments for hereditary pathologies. On GURU.Markets, the EBITDA trend visualizes the scaling potential of gene therapy, where the current status is 0.00. Business stability relies on the ownership of CRISPR patents and a strong scientific foundation. Meanwhile, the company's success is based on R&D pipeline results and strict control over the expenditure of existing cash reserves.

Intellia Therapeutics (NTLA) is developing high-risk CRISPR technologies, where the lack of profitability depends on the outcome of clinical trials. This indicator measures the actual cash flow from core operations before depreciation and interest. Negative values signal high development costs and a reliance on external financing. Investors should assess the burn rate via the annual EBITDA figure. This chart reflects the efficiency of cost management under regulatory pressure.